Abstract
Background and ObjectiveIt is unclear whether early morphological change (EMC) is a predictive marker for regorafenib in metastatic colorectal cancer (mCRC). Therefore, the present study investigated whether EMC can predict the outcome of mCRC patients receiving regorafenib.ResultsThis study evaluated 68 patients. Among 52 patients with lung metastasis, 16 (31%) had cavity formation (CF). The median progression-free survival (PFS) and overall survival (OS) in patients with/without CF were 4.2/2.4 months (p<0.01) and 9.2/6.5 months (p=0.09), respectively. Among 45 patients with liver metastasis, 14 (31%) had active morphological response (MR). The median PFS and OS in patients with/without active MR were 5.3/2.4 months (p<0.01) and 13.6/6.9 months (p=0.02), respectively. Overall, 25 patients (37%) had EMC. The median PFS and OS in patients with/without EMC were 5.3/2.1 months (p<0.01) and 13.3/6.1 months (p<0.01), respectively.Materials and MethodsThis retrospective study included mCRC patients with lung and/or liver metastases receiving regorafenib. CF in lung metastasis and MR in liver metastasis were evaluated at the first post-treatment computed tomography scan. EMC was determined as CF and/or active MR. We compared PFS and OS between patients with and those without EMC.ConclusionsEMC could be a useful predictive marker for regorafenib in mCRC.
Highlights
Colorectal cancer is the third most common cancer and the fourth leading cause of cancer-related mortality worldwide [1]
After excluding 28 patients who were not eligible (Figure 1), 68 patients were recruited in this study
The median period between the start of regorafenib therapy and the first post-treatment computed tomography (CT) scan was 55 (20-133) days and this was comparable between the subgroup with and that without morphological change in each analysis
Summary
Colorectal cancer is the third most common cancer and the fourth leading cause of cancer-related mortality worldwide [1]. Regorafenib showed a disease control rate (DCR) of 41–51%. It caused some unfavourable side effects, such as hand-foot skin reaction, fatigue, hypertension and diarrhoea, which could worsen a patient’s general condition and quality of life [4, 5]. Predictive markers for mCRC patients treated www.impactjournals.com/oncotarget with regorafenib are desired, but such markers have not yet been elucidated [6]. It is unclear whether early morphological change (EMC) is a predictive marker for regorafenib in metastatic colorectal cancer (mCRC). The present study investigated whether EMC can predict the outcome of mCRC patients receiving regorafenib
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
